RedShift BioAnalytics

About:

RedShift BioAnalytics is a developer and manufacturer of bioanalytical tools for the life science market.

Website: http://www.redshiftbio.com/

Twitter/X: redshiftbio

Top Investors: Alta Partners, Illumina Ventures, Waters Corporation, InterWest Partners, Vesbridge Partners

Description:

RedShiftBio provides an infrared technology with advanced data analytics to facilitate better, faster decision making in biopharmaceutical development from discovery to market via the direct measurement of previously undetectable change in protein structural attributes critical to drug product efficacy and quality. It has developed a Microfluidic Modulation Spectroscopy (MMS) platform in response to a customer’s request for a better solution, and rather than repurpose outdated tools and methods designed originally for other applications. They started a new and developed MMS from the ground up specifically with the protein scientist in mind. The company was founded in 2005 and is headquartered in Burlington, Massachusetts.

Total Funding Amount:

$65.7M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Burlington, Massachusetts, United States

Founded Date:

2005-01-01

Contact Email:

info(AT)redshiftbio.com

Founders:

Chip Marshall, Eugene Ma, Matthias Wagner, Stuart Nixdorff

Number of Employees:

1-10

Last Funding Date:

2021-10-18

IPO Status:

Private

Industries:

© 2025 bioDAO.ai